Knight Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
100 Boul Alexis-Nihon Bureau 600, Saint-...Phone Number
(514) 484-4483Website
www.gud-knight.comRevenue
$360 MillionStock Symbol
GUDIndustry
About Knight Therapeutics
Knight Therapeutics is a leading pan-American specialty pharmaceutical company focused on providing innovative therapies in Canada and Latin America. The company develops and commercializes a range of pharmaceutical products, including the recently launched JORNAY PM, an extended-release formulation of methylphenidate. Knight Therapeutics aims to address the unique healthcare needs of patients in these regions. Their target clients include healthcare providers and patients requiring specialized medications.Explore more
Knight Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Knight Therapeutics
Compare insights from companies similar to Knight Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Knight Therapeutics Tech Stack
A closer look at the technologies used by Knight Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Knight Therapeutics
Sign Up For FreeTo access detailed company insights
Knight Therapeutics is a leading pan-American specialty pharmaceutical company focused on providing innovative therapies in Canada and Latin America. The company develops and commercializes a range of pharmaceutical products, including the recently launched JORNAY PM, an extended-release formulation of methylphenidate. Knight Therapeutics aims to a... Read More
